Group 1 - The core point of the article is that 加科思-B (01167) experienced a 5.04% increase in stock price, reaching 7.50 HKD, with a trading volume of 42.24 million HKD [1] - The company announced that it will present preclinical data on its Pan-KRAS inhibitor JAB-23E73 at the 2025 American Association for Cancer Research International Molecular Targets and Cancer Therapeutics Conference in Boston from October 22 to October 26, 2025 [1] - 加科思 has signed an agreement with 海松资本 and an industry partner for a capital increase and equity transfer, where 海松资本 will pay 125 million RMB as an initial payment and 75 million RMB as a milestone payment to acquire 80% of 加科瑞康, reducing 加科思's stake in 加科瑞康 to 10% [1] Group 2 - The divestment of non-core assets allows the company to focus more strategically on the oncology field and enhances its cash flow [1]

Group 1 - The stock of Gacos-B (01167.HK) rose over 5% in early trading, specifically increasing by 5.32% to reach HKD 7.52 [1] - The trading volume amounted to HKD 41.5824 million [1]

Core Viewpoint - 加科思-B (01167) shares rose over 5% following the announcement of their participation in the 2025 American Association for Cancer Research conference, where they will present preclinical data on their Pan-KRAS inhibitor JAB-23E73 [1] Group 1: Company Developments - 加科思 announced that they will present preclinical data on the oral, absorbable, and potent Pan-KRAS inhibitor JAB-23E73 at the 2025 American Association for Cancer Research conference in Boston from October 22 to October 26, 2025 [1] - The company signed an agreement with Haisheng Capital and an industry partner for a capital increase and equity transfer, where Haisheng Capital will pay a total of RMB 2 billion (1.25 billion upfront and 750 million milestone payment) to acquire 80% of Beijing Jakesi's subsidiary, Jakesi Kang [1] - Following the completion of this transaction, 加科思's ownership in Jakesi Kang will decrease to 10%, allowing the company to focus more on its core oncology business and improve cash flow [1]

Core Viewpoint - Multiple companies, including China Feihe and Lianyi Rong Technology, conducted share buybacks on October 24, 2025, with China Feihe leading in both the number of shares repurchased and the total amount spent [1][2]. Group 1: Buyback Details - China Feihe (06186) repurchased 5.885 million shares for a total of 23.6977 million yuan, representing 0.087% of its total share capital [2]. - Lianyi Rong Technology (09959) repurchased 2.4 million shares for 7.3782 million yuan, accounting for 3.516% of its total share capital [2]. - Beike-W (02423) repurchased 1.1784 million shares for 7 million yuan, which is 1.722% of its total share capital [2]. Group 2: Other Notable Buybacks - Yum China (09987) repurchased 17,800 shares for 6.2549 million yuan, representing 2.830% of its total share capital [2]. - Mengniu Dairy (02319) repurchased 400,000 shares for 5.7447 million yuan, which is 0.545% of its total share capital [2]. - Kangsong Pharmaceutical (01681) repurchased 100,000 shares for 1.5180 million yuan, accounting for 8.582% of its total share capital [2].

Core Viewpoint - The company, 加科思-B (01167), announced a share buyback plan, indicating a strategic move to enhance shareholder value through repurchasing its own shares at a specified price range [1] Group 1: Share Buyback Details - The company will repurchase a total of 138,000 shares [1] - The total expenditure for the buyback is HKD 981,400 [1] - The price range for the repurchase is set between HKD 7.08 and HKD 7.16 per share [1]

Core Viewpoint - The company, 加科思-B (01167), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Share Buyback Details - The company will repurchase 138,000 shares at a total cost of HKD 981,400 [1] - The buyback price per share ranges from HKD 7.08 to HKD 7.16 [1] - The buyback is scheduled for October 24, 2025 [1]

Core Viewpoint - 加科思-B (01167.HK) announced a share buyback of 138,000 shares at a cost of HKD 981,000 on October 24 [1] Group 1 - The company executed a buyback program on October 24 [1] - The total expenditure for the buyback was HKD 981,000 [1] - The number of shares repurchased was 138,000 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 加科思藥業集團有限公司 呈交日期： 2025年10月24日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01167 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | | | | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件 ...

Core Insights - The company will present preclinical data on its oral, potent pan-KRAS inhibitor JAB-23E73 at the 2025 AACR-NCI-EORTC conference in Boston from October 22 to October 26, 2025 [1] - The abstract will be released on October 22, 2025, and the poster will be displayed on October 23, 2025, highlighting the drug's selectivity and efficacy [1] Company Overview - JAB-23E73 demonstrates exceptional antitumor activity across various cancer types with different KRAS mutations or amplifications [2] - The drug effectively induces tumor regression in KRAS-driven mouse tumor models without significant weight changes, indicating good tolerability and a wide therapeutic window [2] - JAB-23E73 has favorable pharmacokinetic characteristics for oral administration, with its tumor p-ERK inhibition regulated by plasma concentration [2] - Phase I clinical trials for JAB-23E73 targeting advanced solid tumors with KRAS mutations are currently underway in China and the United States [2]

Core Insights - The company will present preclinical data on its Pan-KRAS inhibitor JAB-23E73 at the 2025 AACR-NCI-EORTC conference in Boston from October 22 to October 26, 2025 [1] - JAB-23E73 is characterized as a highly potent and orally bioavailable inhibitor with strong selectivity for KRAS, avoiding inhibition of HRAS and NRAS [1][2] Company Developments - JAB-23E73 has demonstrated exceptional antitumor activity across various cancer types with different KRAS driver mutations or amplifications [2] - In mouse tumor models driven by KRAS, JAB-23E73 effectively induces tumor regression without significant weight changes, indicating good tolerability and a wide therapeutic window [2] - The drug exhibits favorable pharmacokinetic properties for oral administration, with its effect on tumor p-ERK inhibition regulated by plasma concentration [2] - Phase I clinical trials for JAB-23E73 targeting advanced solid tumors with KRAS mutations are currently underway in China and the United States (NCT06959615, NCT06973564) [2]